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Pilot Project Funding Opportunities 
 
September 20, 2012 
 
Nate Hafer, PhD 
Director of Operations 
UMCCTS 
Pilot & Collaborative  
Translational & Clinical Studies 
Programs 
• Pilot Project Program (PPP) 
• Life Science Moment Fund (LSMF) 
• Pfizer CTI Program 
• Next Hundred Million Pilot Projects (NHMPP) 
1. Life Sciences Moment Fund   $1.9M 
 
2. Pilot Project Program   $2.4 M 
 
3. WPI/UMMS Collaborative Pilot Project Program   $600K 
UMCCTS Pilot Grant Programs 
2009-2012 
Pilot Project Program 
Specific Aims: 
1. Stimulate the development of new clinical and translational 
inter- and multi-disciplinary teams 
2. Provide novel support mechanisms for junior investigators 
3. Increase the emphasis on pilot funding for community-based 
research 
4. Develop new methodologies to leverage institutional strengths 
and new initiatives 
5. Pursue high-risk, high reward studies 
6. Support projects utilizing the unique core facilities at the 
medical school and throughout the University 
7. Encourage collaboration across the five UMass campuses 
Individual Proposals $100,000 max for 1year 
    $150,000 max for 2 years 
 
Projects span the translational spectrum, T1 – T4+ 
 
2 Stages 
Letter of Intent (2 pages) 
Full Proposal (Abbreviated NIH-style 10 pages) 
Pilot Project Program 
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Pilot Project Program – success rate 
2012 Pilot Program Project Recipients  
UMMS Collaborator(s)/Dept UMass Collaborator/Dept Project Title 
Hua (Julia) Fang, PhD 
Department of Quantitative Health Sciences 
DiFranza, Moormann, Ma, Kim, Houston, 
Barton, Allison, Ash 
A New Tool for Studying Heterogeneity of 
Treatment Effects in Longitudinal 
Translational Research 
Brian Lewis, PhD 
Program in Gene Function and Expression 
Venu Bathini, MD 
Department of Medicine 
 
Combined Inhibition of MEK and IGF1Ras 
an Effective Therapeutic Strategy for 
Pancreatic Ductal Adenocarcinoma 
Zuoshang Xu, PhD 
Biochemistry and Molecular Pharmacology 
Guangping Gao, PhD 
MaPS 
Robert Brown, MD, PhD 
Department of Neurology 
Deliver RNAi for Treatment of ALS using 
AAV 
Pilot Project Program (PPP) 
Tentative Timeline: 
Request for Letters of Intent Monday, November 19, 2012 
Letters of Intent Due Thursday, December 20, 2012 
LOI Finalists Notified Friday, January 11, 2013 
Full Proposals Due Friday, February 8, 2013 
Full Proposal Finalists Notified Friday, March 1, 2013 
Project Start Date Monday, April 1, 2013 
UMass Life Sciences Moment Fund 
Funds dedicated to multi-investigator pilot projects identified as 
key strategy to incentivize collaborative partnerships across 
campuses. 
• Inter-campus collaborative projects, involving at least one faculty 
member from the Worcester campus & one faculty member from 
another UMass campus. 
• Collaborative projects must be oriented towards clinical and 
translational research. 
• Funding levels and application review process same as PPP. 
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2012 Life Sciences Moment Fund Recipients  
UMMS Collaborator(s)/Dept UMass Collaborator/Dept Project Title 
Wenjun Li, PhD 
Department of Medicine 
Scott Crouter, PhD, FACSM 
Department of Exercise and Health Sciences, 
Boston Campus 
Residential Environment and Coronary Heart 
Disease Risk Factors (REACH) Pilot Study 
William Theurkauf, PhD 
Program in Molecular Medicine 
Zhiping Weng, PhD 
Biochemistry and Molecular Pharmacology 
Lawrence Schwartz, PhD 
Department of Biology 
Amherst campus 
Priscilla Clarkson, PhD 
Department of Kinesiology 
Amherst campus 
 
microRNA Control of Muscle Atrophy and 
Death 
Tiffany Moore Simas, MD, MPH, MEd 
OB/GYN and Pediatrics 
Ling Shi, PhD 
College of Nursing and Health Sciences, 
Boston campus 
Laura Hayman, PhD, RN, FAAN 
College of Nursing and Health Sciences, 
Boston campus 
Effects of soy protein and isoflavone 
supplementation for improved glucose 
metabolism and lipid profiles in pregnant 
women at high risk for gestational diabetes 
mellitus 
Karl Simin, PhD 
Cancer Biology 
Joseph Jerry, PhD 
Veterinary and Animal Sciences 
Amherst campus  
Gene expression signatures defining high risk 
premalignant breast lesions 
Life Sciences Moment Fund (LSMF) 
Tentative Timeline: 
Request for Letters of Intent Monday, February 11, 2013 
Letters of Intent Due Friday, March 8, 2013 
LOI Finalists Notified Friday, March 29, 2013 
Full Proposals Due Friday, April 26, 2013 
Full Proposal Finalists Notified Tuesday, May 28, 2013 
Project Start Date Monday, July 1, 2013 
CTI STRATEGY 
OPEN INNOVATION model that deploys Pfizer R&D resources 
where breakthrough science is happening 
CTI  APPROACH 
 
A new entrepreneurial partnership at Academic Medical Centers 
focused on translational medicine  
CTI VISION 
 
Accelerate the translation of innovative discoveries from bench to 
the clinic  
Centers for Therapeutic Innovation (CTI) 
Proposals are sought for novel large molecule applications with a path to a clinical 
proof of mechanism study 
Clinical 
Concept 
Mechanisms 
of interest 
Precision 
Medicine 
New and more effective treatments that can induce and maintain remission 
- Prevention of underlying dysregulation of B- and T- cells  
- Modulation of innate immunity 
- Targeting or interruption inducers of persistent immune activation/inflammation 
- Inhibition or modulation of inflammatory processes involved in flares (renal, synovial or 
cutaneous) 
- Regulation of handling and clearance of apoptotic bodies 
- Promotion of immune homeostasis and immunoregulation (i.e., functional tolerance). 
It is preferred if submissions incorporate a hypothesis-driven strategy for patient 
selection, i.e. rationale for patient subset where drug would  be most efficacious 
Inflammation (systemic Lupus Erythematosus/Lupus Nephritis) 
Proposals are sought for novel large molecule applications with a path to a clinical 
proof of mechanism study† 
Clinical 
Concept 
Mechanisms 
of Interest 
Precision 
Medicine 
• Novel approaches (targets, pathways or interventions) that would alter the course of a 
disease which directly or indirectly results in kidney injury and failure 
Renal Disease 
(Kidney Injury/Lupus nephritis, IgA Nephropathy) 
• - Block intrarenal inflammation 
• - Regulation of leukocyte-endothelial cell interactions 
• - Prevention of tubular atrophy and interstitial injury 
• - Inhibition of specific components of the immune response related to renal    damage 
(i.e., aberrant mesangial Ab:IC deposition or handling).    
• - Approaches aimed at promoting responses leading to improved renal function,  such as 
repair and/or restoration of renal epithelium and nephron integrity 
It is preferred if submissions incorporate a hypothesis-driven strategy for patient selection, 
i.e. rationale for patient subset where drug would  be most efficacious 
Proposals are sought for novel large molecule applications with a path to a clinical 
proof of mechanism study 
Clinical 
Concept 
Mechanisms 
of Interest 
Precision 
Medicine 
Cardiac remodeling events post-MI and in CHF leads to progressive deterioration of health 
with few options for patients and physicians.   
• Reduced mortality, CV events, and/or improved cardiac function is the ultimate goal 
• - Those that impact extracellular matrix turnover, fibrosis, restore cardiac tissue & 
 function, apoptosis & proliferation, cardioprotection and neovascularization.  
• - Novel mechanisms that impact endothelial repair (beyond standard of care) such 
 as plaque stabilization and dissolution, mast cell & macrophage regulation 
Defined patient populations at highest risk of CV events that would benefit most from this 
therapeutic approach is required 
Cardiovascular 
(Congestive Heart Failure, Post-Myocardial Infarction and Acute Coronary Syndrome) 
If interested in submitting a proposal, please contact the UMass 
Center for Clinical and Translational Science to inquire about meeting 
with CTI staff prior to submitting a proposal 
– Nathaniel Hafer, nathaniel.hafer@umassmed.edu, 508-856-2511  
 
Pre-proposals due to the UMass Center for Clinical and Translational 
Science by October 19th  
 
 
CTI – Next Steps 
To learn more and obtain the pre-proposal template, please visit 
https://ctipartners.ideareach.com and create a user profile 
• Inter-campus collaborative projects, involving at least one faculty 
member from MassBiologics & one faculty member from the Worcester 
campus. 
• Collaborative projects must be oriented towards clinical and 
translational research. 
 
Individual Proposals $100,000 maximum for 1 year 
   $150,000 maximum for 2 years 
2 Stages 
Letter of Intent (2 pages) 
Full Proposal (Abbreviated NIH-style 10 pages with presentation) 
New UMCCTS-MassBiologics Collaboration 
The Next Hundred Million Pilot Projects 
The Next Hundred Million Pilot Projects 
Tentative Timeline: 
Request for Letters of Intent Monday, August 27, 2012 
Letters of Intent Due Friday, October 5, 2012 
LOI Finalists Notified Monday, October 22, 2012 
Full Proposals Due Wednesday, November 21, 2012 
Full Proposal 
Review/Presentations 
December 2012-January 2013 
Project Start Date February 2013 
Questions? 
Research, Process Development, GMP Manufacturing, Education and Training at
MassBiologics of UMMS
1
An Abridged History of MassBiologics of the UMMS
Dates Name Affiliation
1894 The State Labs‐One lab at the Statehouse and one at the 
Bussey Institute at Jamaica Plain
Massachusetts Department of Health
1895 Theobald Smith, MD arrives as Director of the 
State Labs and Professor of Comparative 
Pathology at the Harvard Veterinary School
1903 The Antitoxin and Vaccine laboratories are launched at 
the Bussey Institute
MA State Department of Health
1917 License #64 to manufacture “Diphtheria antitoxin, 
vaccine virus and bacterial vaccine made from the 
MA State Department of Health
typhoid bacillus”
Theobald Smith, MD Captain
Captain produced enough antitoxin in less than a year to 
protect 86,000 people from diphtheria
An Abridged History of MassBiologics of the UMMS
Dates Name Affiliation
1894 The State Labs‐One lab at the Statehouse and one at the 
Bussey Institute at Jamaica Plain
Massachusetts Department of Health
     
1895 Theobald Smith, MD arrives as Director of the 
State Labs and Professor of Comparative 
Pathology at the Harvard Veterinary School
1903 The Antitoxin and Vaccine laboratories are launched at  MA State Department of Health
the Bussey Institute
1917 License #64 to manufacture “Diphtheria antitoxin, 
vaccine virus and bacterial vaccine made from the 
typhoid bacillus”
MA State Department of Health
1946 The State Laboratories for Plasma Fractionation Edwin J Cohn, PhD, Harvard Medical School
Between 1946 and 
1968
Massachusetts Public Health Biologic Laboratories, 
Institute of Laboratories, Massachusetts Health Research
Massachusetts Department of Public Health, 
Harvard           
Institute 
 
1969 State Laboratory Institute Department of Public Health
3
Edwin J. Cohn, PhD
An Abridged History of MassBiologics of the UMMS
D N Affili iates ame at on
1894 The State Labs‐One lab at the Statehouse and one at the 
Bussey Institute at Jamaica Plain
Massachusetts Department of Health
1895 Theobald Smith, MD arrives as Director of the 
State Labs and Professor of Comparative 
Pathology at the Harvard Veterinary School
1903 The Antitoxin and Vaccine laboratories are launched at 
the Bussey Institute
MA State Department of Health
1917 License #64 to manufacture “Diphtheria antitoxin, 
vaccine virus and bacterial vaccine made from the
MA State Department of Health
               
typhoid bacillus”
1946 The State Laboratories for Plasma Fractionation Edwin J Cohn, PhD, Harvard Medical School
Between 1946 and Massach setts P blic Health Biologic Laboratories Massach setts Department of P blic Health     
1968
u   u       , 
Institute of Laboratories, Massachusetts Health Research 
Institute 
u       u   , 
Harvard 
1969 State Laboratory Institute Department of Public Health
1997‐1998 University of Massachusetts Biologic Laboratories 
(UMBL)/ Massachusetts Biologic Laboratories (MBL)
UMMS
2007 MassBiologics Per FDA License #1779 to produce Td 
vaccine
UMMS
2012 MassBiologics of the UMMS UMMS
MassBiologics Mabs
2002‐ 2010
Monoclonal Antibody  Indication Stage of Development Business Model
1      SARS1 Prevention of SARS
Completed through 
f t i
50/50 collaboration with 
M d t Ph 1
NIH Funded
manu ac ur ng e arax o  ase
2 MBL‐CDA1 and 
3 MBL‐CDB1
Treatment of C. difficile
infection
Phase 3
50/50 collaboration with
Medarex through Phase 2
Merck
April 2009 License, 
Development and 
Commercialization 
Agreement
4     MBL‐RAB1
Rabies post‐exposure 
prophylaxis in 
conjunction with rabies 
Phase 2/3 (India) MBL through discovery
Serum Institute of India
September 2006 
License and 
Collaboration
vaccine
 
Agreement
5      MBL‐HCV1
Prevention and 
treatment of HCV 
infection
Phase 2
MBL 
(collaboration with UMMS)
N/A
T t t f
6       ALS
rea men  o  
Amyotrophic Lateral 
Sclerosis
Preclinical
MBL
(collaboration with UMMS)
N/A
Millions of Life Saving Doses of “Medicine for Better Lives” from 
MassBiologics of UMMS
Diphtheria Antitoxin-Equine
Botulism Antitoxin-Equine
Tetanus Antitoxin-Equine
Rabies Immunoglobulin-Equine
Human Serum Albumin
Human Immune Globulin
Human Hyper-Immune Globulin to Scarlet Fever, Pneumococcus, Meningococcus, 
Tetanus, Measles, CMV, RSV, Varicella-zoster, 
Rabies, Hepatitis A
Tetanus Toxoid Vaccine
Diphtheria Toxoid Vaccine
Td Vaccine
Human Monoclonal Antibodies against SARS, C diff Toxins A and B, Rabies, Hepatitis 
C Tetanus and Diphtheria Toxins SOD1 for,    ,   
ALS, sFlt-1 for Pre-Eclampsia
Going Forward
• Research on Human Monoclonal Antibody Development
• Research and Development of New Therapeutic MAbs-
• Research and Development of New Prophylactic MAbs      
• Innovation in Process Development, Manufacturing
• Innovation in Quality Assessment tools
• Innovation in Business Development
• Emphasis on Training/Mentoring
• Custom Contract Manufacturing
8
“The Next Hundred Million” Pilot Projects
lProcess Deve opment
Human Monoclonal Antibodies
Process Development Overview   
• Focus on proteins produced by CHO cells
– Human monoclonal antibodies
• Cell culture, purification, formulations and 
analytical support
• 4 PhD’s and 13 technicians
• Supplemented by MAb Manufacturing team
• Upstream process development
• Downstream process development
• Analytical method development     
• Formulation development
• Tech Transfer and Manufacturing support
MBL Process Development
Pl tf T h la orm  ec no ogy
• CHO cell expression host and vector           
• Proprietary media and feeds
Ch i ll d fi d i l t f– em ca y  e ne , an ma  componen   ree
• Fed‐batch culture method up to 5 gm/L
• Purification platform for MAbs
• Formulation platform for 25‐100 mg/ml
Bench top DasGip Reactors
Upstream Process 
Development
Small Scale Shaken Cultures
60 L Applikon Reactor
Upstream Process Development Activities
• Cell Line Development (transfection, cloning)
• Cell Line Characterization (growth, production kinetics, max 
ll d i ifi d i i bili )ce   ens ty, spec c pro uct v ty, sta ty, etc
• Process for Seed‐train and Bioreactor (pH, DO, Temp)
• Fed‐batch Bioreactor Optimization (feeding pH DO Temp)      ,  ,  , 
• Material for Downstream and Analytical Process Development
• Process Scalability, Tox material production (IND), and Tech 
transfer (Ph I/II)
CHO Cell Line Selection
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Downstream
Process Development
Current MBL Purification Platform     
Downstream Process Development   
• Optimize chromatography steps   
– Establish set points, ranges and hold times
• Virus inactivation and removal studies
– Prosep, low pH, nanofiltration
• MAb development purification scale >10 g
• Pre‐clinical material (toxicology, reference standard)
Analytical Development 
• Antibody characterization
• Tox lot, reference standards, Mfg in‐process samples
• Support Upstream, Downstream, and Formulation 
Development
• Development of New Assays, Methods
• Comparability Studies
• Improve Throughput of the Assays
Formulation Process Development
• Formulation development 
• High concentration formulations (100 mg/L)
• High throughput analytical for Mabs
• Accelerated stability testing for formulation         
development
• Platform formulation   
– 20 mM citrate, pH 6.0, 150 mM NaCl, Tween 80
Research, Process Development, GMP Manufacturing, Education and Training at
MassBiologics of UMMS
22
1        
MassBiologics, Product Discovery 
Greg Babcock, Ph.D. 
Associate Professor, Medicine, UMMS 
Deputy Director, Discovery, MassBiologics 
2        
Product Discovery 
- Focus is the development of human monoclonal antibodies 
  from initial concept to completion of preclinical activity 
 to support an IND application 
 
- Extensive experience in identifying novel antibody molecules 
 
- Infectious disease targets (mostly but not all) 
 
- Various technologies used for human antibody development 
 
- Four human monoclonal antibodies developed from concept 
 to phase 2 human studies 
3        
HuMAb-Mouse™ 
ms IgH 
ms Igκ 
hu IgH 
hu Igκ 
Four distinct genetic 
modifications functionally 
replace the mouse immunoglobulin loci 
with human immunoglobulin transgenes 
Medarex, A Wholly Owned subsidiary of Bristol-Myers Squibb 
4        
Antibody secreting cells 
Draw blood Day 7 post vaccine 
Perform 1-step RT-PCR on 
ASC-RNA (H+L) 
Perform separate cloning PCRs  
Sort  individual ASCs into 
96-well PCR plates 
Stain PBMCs to isolate ASCs 
Ligate “valid” antibodies into expression vectors 
Transfect to produce antibody 
and screen against Tet/Dip 
toxoid via ELISA 
Run products on gel to determine 
positive clones 
5        
Antibody Pre-Clinical Phase 1 Phase 2 Phase 3 
Clostridium difficile 
antibody combination 
                          
                  Licensed to Merck 
                          
Rabies virus 
                  
Licensed to Serum 
Institute of India                   
                  
Hepatitis C virus 
                          
                          
                          
SARS virus 
                          
                          
                          
anti-hSOD1 (ALS) 
                          
                          
                          
Discovery Target #1 - 
Infectious Disease 
                          
                          
                          
Discovery Target #2 - 
Infectious Disease 
                          
                          
                          
Discovery Target #3 - 
Endogenous Target 
                          
                          
                          
MassBiologics Antibody Pipeline 
6        
Ex: HCV mAb Development 
Hybridomasproduced from 51 HuMAb mice
ELISA recognition of CO-E2660
ELISA recognition of E2-1b
Neutralization of HCVpp
Sequence comparison
Antibody cloningand expression
487 hybridomas
50 hybridomas
20 hybridomas
2 hybridomas (HCV1 and 95-2)
Extensive characterization
7        
HCV mAb HCVpp Neutralization 
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8        
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9        
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10        
Product Discovery 
- Skilled in in vitro assays to determine mAb activities 
 
 
- Adept at understanding requirements for animal studies to support 
 human studies 
 
 
-Preparing Pharm-Tox section of IND to the satisfaction of the FDA 
 
 
- Proven track record of developing human monoclonal antibodies 
 from bench to bedside 
